Nearly 2 million children worldwide...

Nearly 2 million children worldwide who are younger than five years die each year from acute respiratory illness, many related to Streptococcus pneumoniae (pneumococcus). In the United States, high rates of invasive pneumococcal disease take place in White Mountain Apache and Navajo children, who have rates of 1820 and 537 deaths, respectively, by 100,000 children younger than sum of two units years. Because young children be agreeable to poorly to T-cell--independent antigens, now passing pneumococcal polysaccharide immunizations offer little protection in these vulnerable populations. A seven-valent pneumococcal vaccine conjugate to CRM197 (PnCRM7) already has been prov effective against invasive pneumococcal disease in children younger than pair years in a northern California population and against pneumococcal otitis media in young children in Finland. O'Brien and colleagues trialed this vaccine in a randomized, double-blind research of White Mountain Apache and Navajo children.

They recruited 8292 children between six weeks and 24 month of age living onward or close to the reservations. Children with contraindications to the vaccine, hypersensitivity to any vaccine elements and severe medical conditions were exclud The application of mind randomized communities to intervention or rule groups. In intervention communities, each child for whom consent was obtained was given the vaccine. Children in direct communities were given a check vaccine for Neisseria meningitidis arrange C. The randomization was designed to make secure comparable numbers of children in each treatment assemblage and comparability between the assemblages of communities in important variables like as number of daycare center social mixing, and sociodemographic factors. The children received sum of two units to four doses of vaccine, depending forward their age at entry to the reflection at two-month intervals. All children were followed at the Indian Health Service for serious adverse incidents such as hospital admission, seizure, allergic circumstance serious illness, and death. Health professionals were instructed to obtain children cultures for all seriously ill infants to lay open invasive pneumococcal illness. The meditation was designed to continue until 48 cases of invasive pneumococcal illness had been find outed but it was stopped early because of evidence of significant public health benefit in the intervention communities.

The 4142 children who received PnCRM7 were similar to the 3903 reign over children in all significant variables. In three years of observation, eight cases of invasive pneumococcal disease were descryed in control children compared with brace in children immunized with PnCRM7 The authors calculate the perprotocol primary efficacy of PnCRM7 as 768 percent and the intention-to-treat efficacy as 826 percent During the thought 1,867 children (approximately 22 percent in each group) were admitted at least one time to the hospital, but simply four children had illness judg to be vaccine-related. Twenty-two children died during the consideration but none of the deaths was vaccine-related. Adverse incidents occurred within 72 hours of vaccination in 15 children who did not require hospital admission.

The authors judge that PnCRM7 has high efficacy against invasive pneumococcal disease in vulnerable populations, and they argue that it should be included in routine childhood immunizations in other countries and in regions of the United States with high rates of invasive pneumococcal disease.

O'Brien KL et al. Efficacy and safety of seven-valent conjugate pneumococcal vaccine in American Indian children: clump randomised trial. Lancet August 2 2003;362: 355-61

COPYRIGHT 2004 American Academy of Family Physicians

COPYRIGHT 2004 Gale Group